NCT07446049

A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: Convalife (Shanghai) Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, open-label, multicenter, Phase Ib/II clinical trial of CVL237 tablets in combination with serplulimab injection for the treatment of advanced solid tumors with PTEN loss or low expression

Detailed description

A single-arm, open-label, multicenter, Phase Ib/II clinical trial of CVL237 tablets in combination with serplulimab injection for the treatment of advanced solid tumors with PTEN loss or low expression

Conditions

• Locally Advanced or Metastatic Solid Tumors
• PTEN Loss or Low Expression

Interventions

Type	Name	Description
DRUG	CVL237 tablets	CVL237 tablets, 200 mg, taken with food once daily for 28 consecutive days as a treatment cycle.

Timeline

• Start date: 2026-05-01
• Primary completion: 2028-01-09
• Completion: 2028-04-08
• First posted: 2026-03-03
• Last updated: 2026-03-03